May 23, 2024 01:52AM
May 16, 2024 11:22AM
May 15, 2024 07:30AM
Apr 24, 2024 03:26AM
Mar 11, 2024 09:28PM
Mar 6, 2024 02:34AM
Feb 21, 2024 01:43AM Calliditas Year-end report, January - December 2023
Jan 8, 2024 05:17AM
Jan 7, 2024 11:19AM
Dec 27, 2023 12:17PM
Dec 27, 2023 12:16PM
Dec 20, 2023 09:30PM
Dec 20, 2023 04:35PM
Dec 20, 2023 04:33PM Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
Nov 30, 2023 02:49AM
Nov 7, 2023 01:29AM
Oct 23, 2023 09:33AM
Oct 19, 2023 03:58AM
Sep 29, 2023 08:17AM
Sep 27, 2023 01:34PM
Sep 27, 2023 01:33PM Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib
Sep 19, 2023 10:33AM
Aug 20, 2023 08:19PM
Aug 18, 2023 04:17AM
Aug 17, 2023 01:29AM
Aug 15, 2023 04:57AM
Aug 15, 2023 04:50AM
Jul 13, 2023 02:17AM Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Jun 21, 2023 06:02AM
Jun 21, 2023 04:10AM
Jun 20, 2023 08:15PM
May 30, 2023 10:16AM
May 16, 2023 01:14AM
May 5, 2023 09:00AM
Apr 28, 2023 04:51AM Notice of annual general meeting of Calliditas Therapeutics AB (publ)
Apr 26, 2023 06:15PM
Apr 11, 2023 09:43AM
Mar 31, 2023 11:20AM
Mar 14, 2023 05:23AM
Mar 13, 2023 07:30PM
Mar 12, 2023 11:06PM
Feb 23, 2023 01:34AM Calliditas - Year-End Report, 2022
Feb 2, 2023 05:41AM
Feb 2, 2023 03:44AM
Jan 31, 2023 02:22AM
Dec 30, 2022 03:00AM
Dec 30, 2022 02:16AM
Dec 20, 2022 10:06PM
Dec 13, 2022 03:01AM Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan
Dec 9, 2022 02:09AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All